

Applicants: Michael J. Elliott, et al.  
U.S. Serial No.: 08/602,272  
Filed: February 16, 1996  
Page 2

a tumor necrosis factor antagonist to the subject.

8. The method of claim 6, wherein the tumor necrosis factor antagonist is an anti-tumor necrosis factor antibody or antigen-binding fragment thereof.
9. The method of claim 8, wherein the antibody is selected from the group consisting of a humanized antibody and a resurfaced antibody or antigen-binding fragment thereof.
10. The method of claim 8, wherein the antibody binds to an epitope included in amino acid residues of about 87-108 (SEQ ID NO:1) or about 59-80 (SEQ ID NO:2) of hTNF $\alpha$ .
12. The method of claim 8, wherein the antibody is a chimeric antibody, said chimeric antibody comprising (a) a non-human variable region specific for TNF or an antigen-binding portion thereof and (b) a human constant region.
13. The method of claim 12, wherein the chimeric antibody binds to an epitope included in amino acid residues of about 87-108 (SEQ ID NO:1) or about 59-80 (SEQ ID NO:2) of hTNF $\alpha$ .
14. The method of claim 12, wherein the chimeric antibody is monoclonal antibody cA2.
- 21 15. (Thrice Amended) The method of claim 12, wherein the chimeric antibody competitively inhibits binding of TNF $\alpha$  to monoclonal antibody cA2.

Applicants: Michael J. Elliott, et al.  
U.S. Serial No.: 08/602,272  
Filed: February 16, 1996  
Page 3

29. A method of decreasing plasma fibrinogen in a subject diagnosed as suffering from or at risk of thrombosis comprising administering a therapeutically effective amount of a tumor necrosis factor antagonist to the subject.
30. The method of claim 29, wherein the tumor necrosis factor antagonist is an anti-tumor necrosis factor antibody or antigen-binding fragment thereof.
31. The method of claim 30, wherein the antibody is selected from the group consisting of a humanized antibody and a resurfaced antibody or antigen-binding fragment thereof.
32. The method of claim 30, wherein the antibody binds to an epitope included in amino acid residues of about 87-108 (SEQ ID NO:1) or about 59-80 (SEQ ID NO:2) of hTNF $\alpha$ .
34. The method of claim 30, wherein the antibody is a chimeric antibody, said chimeric antibody comprising (a) a non-human variable region specific for TNF or an antigen-binding portion thereof and (b) a human constant region.
35. The method of claim 34, wherein the chimeric antibody binds to an epitope included in amino acid residues of about 87-108 (SEQ ID NO:1) or about 59-80 (SEQ ID NO:2) of hTNF $\alpha$ .
36. The method of claim 34, wherein the chimeric antibody competitively inhibits binding of TNF $\alpha$  to monoclonal antibody CA2.